Wexford Capital LP acquired a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,922 shares of the company’s stock, valued at approximately $230,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Apogee Therapeutics during the third quarter worth $71,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apogee Therapeutics by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock valued at $94,000 after purchasing an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Apogee Therapeutics in the second quarter worth $143,000. Arizona State Retirement System boosted its holdings in Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after purchasing an additional 258 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after buying an additional 1,340 shares in the last quarter. Institutional investors own 79.04% of the company’s stock.
Apogee Therapeutics Trading Up 6.0 %
NASDAQ APGE opened at $49.97 on Friday. The business’s 50-day moving average price is $52.41 and its two-hundred day moving average price is $48.31. The firm has a market capitalization of $2.25 billion, a PE ratio of -20.65 and a beta of 2.30. Apogee Therapeutics, Inc. has a 12 month low of $19.91 and a 12 month high of $72.29.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on APGE
Insider Buying and Selling at Apogee Therapeutics
In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $46.58, for a total transaction of $698,700.00. Following the completion of the sale, the chief executive officer now directly owns 1,324,487 shares in the company, valued at approximately $61,694,604.46. This trade represents a 1.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Carl Dambkowski sold 6,665 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $59.12, for a total value of $394,034.80. Following the completion of the transaction, the insider now directly owns 267,463 shares in the company, valued at $15,812,412.56. This represents a 2.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 89,995 shares of company stock valued at $4,912,264. 36.10% of the stock is currently owned by company insiders.
About Apogee Therapeutics
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
See Also
- Five stocks we like better than Apogee Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- Trinity Capital CEO on Leading Private Credit’s High-Yield Growth
- Industrial Products Stocks Investing
- Lululemon Surges On Q3 Report: Analysts Step in To Support Market
- Ride Out The Recession With These Dividend Kings
- 10 Safe Investments with High Returns
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.